A T Lachand1, J Texier, P Texier. 1. Clinique Sarrette, Compagnie Générale de Santé, 23, rue du Père Corentin, 75014 Paris. tibere@easynet.fr
Abstract
OBJECTIVE: Define the prognostic factors (risk of recurrence and risk of progression) and the rules for surveillance of stage T1 papillary bladder tumours based on the clinical course of a homogeneous patient series. MATERIAL AND METHOD: 88 T1 bladder tumours recruited from 1975 to 1995 and regularly followed by the same urologist. The follow-up ranged from 1 to 22 years with a mean of 52 months and a median of 48 months. RESULTS: 26% patients relapsed (mean follow-up: 71 months) 74% developed one or more recurrences (mean follow-up: 48 months) with recurrences staged > T1 in 35% of cases. 29/88 patients died from invasive bladder cancer, 14 before 3 years, 19 before 5 years, 28 before 10 years. The risk of recurrence and progression was statistically significantly related to the macroscopic appearance of the tumour; size, number and extent of implantations; its rate of progression assessed by the frequency of recurrence. In patients with no recurrence at 12 months, the risk of recurrence decreased from 74% to 50% and the risk of progression decreased from 35% to 20%. In this cohort, neither histological grading of the initial tumour, nor the degree of invasion of the submucosal lamina propria appeared to modify the prognosis. CONCLUSION: Stage T1 papillary bladder tumours, generally considered to be a superficial tumours regardless of their histological grade, have a serious prognosis and warrant close endoscopic surveillance during the year following the diagnosis. The subsequent frequency of follow-up can then be adapted to the specific mode of progression of each case, but, regardless of this mode of progression, the authors recommend long-term (life-long?) surveillance.
OBJECTIVE: Define the prognostic factors (risk of recurrence and risk of progression) and the rules for surveillance of stage T1 papillary bladder tumours based on the clinical course of a homogeneous patient series. MATERIAL AND METHOD: 88 T1 bladder tumours recruited from 1975 to 1995 and regularly followed by the same urologist. The follow-up ranged from 1 to 22 years with a mean of 52 months and a median of 48 months. RESULTS: 26% patients relapsed (mean follow-up: 71 months) 74% developed one or more recurrences (mean follow-up: 48 months) with recurrences staged > T1 in 35% of cases. 29/88 patients died from invasive bladder cancer, 14 before 3 years, 19 before 5 years, 28 before 10 years. The risk of recurrence and progression was statistically significantly related to the macroscopic appearance of the tumour; size, number and extent of implantations; its rate of progression assessed by the frequency of recurrence. In patients with no recurrence at 12 months, the risk of recurrence decreased from 74% to 50% and the risk of progression decreased from 35% to 20%. In this cohort, neither histological grading of the initial tumour, nor the degree of invasion of the submucosal lamina propria appeared to modify the prognosis. CONCLUSION: Stage T1 papillary bladder tumours, generally considered to be a superficial tumours regardless of their histological grade, have a serious prognosis and warrant close endoscopic surveillance during the year following the diagnosis. The subsequent frequency of follow-up can then be adapted to the specific mode of progression of each case, but, regardless of this mode of progression, the authors recommend long-term (life-long?) surveillance.
Authors: Nikhil Vasdev; Jose Dominguez-Escrig; Edgar Paez; Mark I Johnson; Garrett C Durkan; Andrew C Thorpe Journal: Ecancermedicalscience Date: 2012-09-18